Systemic Mastocytosis: State of the Art.

Abstract excerpt

PURPOSE OF REVIEW: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic C-KIT D816V mutation. RECENT FINDINGS: Avapritinib, the first licensed drug in SM capable of disease modification alongside the increasingly potent, oral and highly selective KIT tyrosine kinase...

Topics

Join the communities discussing this publication.

• Disease Management
• Mastocytosis, Systemic
• Molecular Targeted Therapy
• Mutation
• Protein Kinase Inhibitors